Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$26.39M

FY 2025 · Annual

Investing Cash Flow

-$2.03M

FY 2025 · Annual

Financing Cash Flow

-$15,268.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Depreciation & Amortization09.27K12.04K10.88K16.25K
Deferred Income Tax00000
Stock-Based Compensation511.08K976.44K1.08M841.87K1.33M
Change in Working Capital(2.22M)(277.52K)1.78M(3.48M)6.28M
Accounts Receivables00000
Inventory00000
Accounts Payables(866.01K)(787.89K)1.45M(946K)1.1M
Other Working Capital(1.36M)510.37K329.03K(2.53M)5.19M
Other Non-Cash Items3.37M578.52K51.97K14.79M2.11M
Operating Cash Flow(8.8M)(13.55M)(21.05M)(14.56M)(26.39M)
Capital Expenditures(250K)(536.84K)0(14.76M)(33.95K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities000(14.75M)(2M)
Investing Cash Flow(250K)(536.84K)0(14.76M)(2.03M)
Debt Repayment00000
Common Stock Issued53.41M(102.07K)0109.29M(15.27K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow58.39M(102.07K)0109.29M(15.27K)
Effect of Forex Changes050.39K000
Net Change in Cash49.34M(14.14M)(21.05M)79.98M(28.43M)
Free Cash Flow(9.05M)(14.09M)(21.05M)(29.31M)(26.42M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$36.1M
+ D&A$16.3K
+ Stock-Based Comp$1.3M
+ Deferred Tax$0
+ Working Capital$6.3M
+ Other Non-Cash$2.1M
= Operating Cash Flow-$26.4M
- Capex-$33.9K
= Free Cash Flow-$26.4M

Analysis

FY2025 free cash flow is -$26.4M. FCF conversion is 73.1% of net income. Operating cash flow was -$26.4M, with capex of -$33.9K. The largest bridge item is Working Capital at $6.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipJun 26, 2026
4Statement of changes in beneficial ownershipJun 26, 2026
4Statement of changes in beneficial ownershipJun 26, 2026
4Statement of changes in beneficial ownershipJun 26, 2026
8-KCurrent reportJun 26, 2026

Does CNTX generate free cash flow?

Context Therapeutics Inc. (CNTX) generated -$26.42M of free cash flow in fiscal 2025.

How much operating cash flow does CNTX produce?

Operating cash flow was -$26.39M, before capital expenditures of $33,948.00.